Tracheobronchomalacia (TBM) is characterized by generalized or focal airway wall weakness, resulting in excessive variation of the luminal diameter during the respiratory cycle. The weakness of the trachea is due to a reduction and/or atrophy of the longitudinal elastic fibers or impaired cartilage integrity so that the airway become softer and more susceptible to collapse.\[[@ref1][@ref2]\] This disease may arise congenitally, or it may be acquired due to trauma, infections, or chronic inflammation.\[[@ref3]\] It is seen more commonly in the pediatric population, and the symptoms usually subside with age as the cartilaginous rings become more rigid, with reduction of tracheal wall compliance. Acquired TBM has been reported to be present in 12.7% of all patients undergoing bronchoscopy evaluation for respiratory diseases, and in 44% of patients undergoing bronchoscopy who have a history of chronic bronchitis.\[[@ref3]\]

TBM has been associated with airway inflammatory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. Chronic airway inflammation might play a role in exacerbations of these disorders. TBM acquired in the background of such inflammation results in persistence of symptoms.\[[@ref4]\] TBM is associated with a substantial invagination of the posterior wall of the tracheobronchial tree which is called excessive dynamic airway collapse (EDAC).\[[@ref5]\] The clinical impact of these abnormalities is quite high. The pathologic weakening of the airway can produce dynamic outflow obstruction and severe symptoms, in the form of cough, dyspnea, and wheezing. These symptoms are resistant to corticosteroids and inhaled bronchodilators. Clearing of secretions may be affected leading to recurrent pneumonia, atelectasis, or respiratory insufficiency. Air trapping was also observed with greater severity in these patients when compared to patients of similar ages without TBM.\[[@ref6]\] Up to 7% of patients with severe TBM may require mechanical ventilation due to respiratory failure.\[[@ref7]\]

Although bronchoscopy is widely used to diagnose TBM, recent advances in computed tomography (CT) imaging can be used as a noninvasive investigation to diagnose this entity with a high level of accuracy.\[[@ref8]\] Dynamic CT of the chest exhibits tracheal collapse with crescentic bowing of the posterior membranous trachea during expiration.\[[@ref9]\] Examining the airway with flexible bronchoscopy during passive exhalation can confirm collapse of the central airway typical of TBM.

The presence of TBM or EDAC should be considered whenever COPD or asthma persists even after appropriate pharmacological intervention. Current treatments include techniques that splint the central airways such as continuous positive pressure ventilation,\[[@ref10]\] silicone airway stents,\[[@ref11]\] and surgical tracheobronchoplasty.\[[@ref12]\] Surgical central airway stabilization with posterior tracheobronchial splinting using a polypropylene mesh improves the symptoms.

In this issue of the journal, result of a pilot study on the influence of TBM and EDAC in patients of COPD is presented. This study is based on the hypothesis that TBM/EDAC may be a cause of persistent wheeze in patients with obstructive airway disorders even after optimal medical management. The authors conclude that 40% of their patients with persistent wheeze have features of TBM/EDAC. Even though they could not find any significant correlation with severity of disease and exacerbation, it is postulated that identification of TBM/EDAC in COPD may provide additional treatment options. It could have been better if COPD without persistent wheeze were also included in this study so that the true impact of TBM/EDAC in COPD could be ascertained.
